Bimekizumab
- Generic Name
- Bimekizumab
- Brand Names
- Bimzelx
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1418205-77-2
- Unique Ingredient Identifier
- 09495UIM6V
- Background
Bimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in the EU on August 20, 2021, for the treatment of plaque psoriasis. It is the first IL-17 inhibitor to target both IL-17A and IL-17F. It has demonstrated superior efficacy as compared to another IL-17 inhibitor, secukinumab, as well as ustekinumab (an IL-12/23 ...
- Indication
Bimekizumab is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
- Associated Conditions
- Severe Plaque psoriasis, Moderate Plaque psoriasis
- Associated Therapies
- -
A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2018-01-25
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 435
- Registration Number
- NCT03410992
- Locations
- 🇵🇱
Ps0013 361, Białystok, Poland
🇷🇺Ps0013 402, Moscow, Russian Federation
🇵🇱Ps0013 359, Katowice, Poland
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2017-12-12
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 567
- Registration Number
- NCT03370133
- Locations
- 🇭🇺
Ps0009 253, Orosháza, Hungary
🇯🇵Ps0009 607, Chiyoda, Japan
🇯🇵Ps0009 620, Hamamatsu, Japan
A Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing Spondylitis
- First Posted Date
- 2017-11-28
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 255
- Registration Number
- NCT03355573
- Locations
- 🇵🇱
As0009 453, Elblag, Poland
🇨🇿As0009 201, Praha 4, Czechia
🇵🇱As0009 460, Wroclaw, Poland
A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis
- First Posted Date
- 2017-11-20
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 184
- Registration Number
- NCT03347110
- Locations
- 🇨🇿
Pa0009 205, Brno, Czechia
🇨🇿Pa0009 207, Olomouc, Czechia
🇺🇸Pa0009 013, Mesquite, Texas, United States
A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.
- Conditions
- Interventions
- First Posted Date
- 2017-08-14
- Last Posted Date
- 2022-04-11
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 90
- Registration Number
- NCT03248531
- Locations
- 🇺🇸
Hs0001 115, Las Vegas, Nevada, United States
🇧🇪Hs0001 203, Brussels, Belgium
🇳🇴Hs0001 701, Harstad, Norway
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis
- First Posted Date
- 2017-07-26
- Last Posted Date
- 2022-07-22
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 43
- Registration Number
- NCT03230292
- Locations
- 🇦🇺
Ps0018 101, Carlton, Australia
🇨🇦Ps0018 201, Ajax, Canada
🇦🇺Ps0018 103, East Melbourne, Australia
A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis
- Conditions
- Interventions
- First Posted Date
- 2017-07-12
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 76
- Registration Number
- NCT03215277
- Locations
- 🇬🇷
As0013 406, Thessaloníki, Greece
🇵🇱As0013 708, Białystok, Poland
🇵🇱As0013 709, Kraków, Poland
A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis
- First Posted Date
- 2017-01-19
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 49
- Registration Number
- NCT03025542
- Locations
- 🇦🇺
Ps0016 102, Kogarah, Australia
🇺🇸Ps0016 704, Bexley, Ohio, United States
🇦🇺Ps0016 101, Melbourne, Australia
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis
- First Posted Date
- 2017-01-05
- Last Posted Date
- 2022-10-18
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 217
- Registration Number
- NCT03010527
- Locations
- 🇺🇸
Ps0011 709, Houston, Texas, United States
🇺🇸Ps0011 733, Dallas, Texas, United States
🇵🇱Ps0011 608, Krakow, Poland
A Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis
- First Posted Date
- 2016-11-21
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- UCB Biopharma S.P.R.L.
- Target Recruit Count
- 206
- Registration Number
- NCT02969525
- Locations
- 🇵🇱
Pa0008 454, Warszawa, Poland
🇺🇸Pa0008 014, Portland, Oregon, United States
🇨🇿Pa0008 201, Praha 4, Czechia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.